Immunological evaluation of patients with osteosarcoma received adjuvant treatment with specific Transfer Factor. (41.63)

Abstract

Abstract Osteosarcoma is a malignant bone tumor with a tendency to metastasis. Based on the immune response and the degree of progress in primary injury Levin developed a classification for osteosarcoma ranging from Phase I to Phase IV associated with the loss of the immune response of cytotoxic cell type and primarily to the development of metastases. Transfer Factor is a polypeptide with a molecular weight of about 6 kilodalton present in dialyzable leukocyte extract the human capacity for immunoregulation. The present study is conducting a pilot clinical trial evaluating the different populations and lymphocyte subpopulations in peripheral blood at baseline and post-surgical type, neoadjuvant chemotherapy and specific transfer factor. So far 16 patients have been assessed, of which it was found that 62.5 percent have decreased the number of lymphocyte cells, T lymphocytes, 44 percent and 68.8 percent total cytotoxic and helper response at baseline compared to healthy individuals. After treatment we observed that 63 percent of patients increased the number of T lymphocytes, 75 percent increased their cytotoxic T lymphocytes and 50 per cent of these cells cooperating. The 87.5% of patients come back to phase I of Levins classification